Loading...
Market
Story
Pfizer Raises Full-Year Guidance After Beating Q3 Estimates with 31% Revenue Growth and Adjusted EPS of $1.06
Oct 29, 2024, 11:23 AM
Pfizer Inc. reported strong third-quarter 2024 results, significantly surpassing earnings estimates and raising its full-year guidance. The company posted Q3 revenue of $17.7 billion, up 31% year-over-year, against an estimated $15.2 billion. Adjusted earnings per share (EPS) for the quarter were $1.06, exceeding the forecast of $0.64. The reported diluted EPS was $0.78. Pfizer increased its full-year 2024 revenue guidance to a range of $61.0 billion to $64.0 billion, up from the previous range of $59.5 billion to $62.5 billion. The adjusted EPS guidance was also raised to $2.75 to $2.95, from the prior range of $2.45 to $2.65. The company's performance was bolstered by sales from its Covid vaccine and Paxlovid, contributing roughly $5 billion and $5.5 billion respectively. The third-quarter revenues represented 32% year-over-year operational growth.
View original story
Similar markets
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
Negative growth • 25%
0-5% growth • 25%
5-10% growth • 25%
Over 10% growth • 25%
Less than $85 billion • 25%
$85 billion to $90 billion • 25%
$90 billion to $95 billion • 25%
More than $95 billion • 25%
Less than 3% • 25%
3% to 4% • 25%
4% to 5% • 25%
More than 5% • 25%
Less than $8 billion • 25%
$8 billion to $10 billion • 25%
$10 billion to $12 billion • 25%
More than $12 billion • 25%
10% - 12% • 25%
13% - 15% • 25%
16% - 18% • 25%
Above 18% • 25%
Less than $60 billion • 25%
$60 billion to $65 billion • 25%
$65 billion to $70 billion • 25%
More than $70 billion • 25%
Paxlovid • 25%
Comirnaty • 25%
Prevnar • 25%
Other • 25%
Less than 50% • 25%
50% to 100% • 25%
100% to 150% • 25%
More than 150% • 25%